战略性新兴产业正在成为深圳产业升级的新支柱。今年上榜的企业中，既有新能源汽车领军者比亚迪和全球动力电池制造商欣 旺达，也有全球无人机巨头大疆，以及生命科学领域的代表华大基因。 深圳方面，今年华为、腾讯、比亚迪、神州数码、欣旺达等5家企业蝉联上榜，同时，大疆、大族激光、顺丰、华大基因等4家 企业首次入选，涵盖通讯、数字科技、新能源汽车、智能装备制造、数智物流和生命科学等多个领域。 深圳被誉为"工业第一城"，长期坚持工业立市、制造业当家，稳步推进新型工业化，加快发展新质生产力。当前，深圳已形成 以高技术制造业、装备制造业为核心的产业体系，并依托华为、比亚迪、大疆等龙头企业，持续推动产业升级与国际化发展。 南山区作为数字经济核心区，2025年上半年GDP达4980.06亿元，其中第三产业（含数字经济）贡献超八成。 8月21日，财富中文网发布了2025年《财富》中国科技50强（排名不分先后）。据记者统计，华为、腾讯、比亚迪（002594）、 大疆、大族激光（002008）、顺丰、神州数码（000034）、欣旺达（300207）、华大基因（300676）等9家深圳企业上榜，深圳 成为上榜企业最多的城市之一。 今年是《财 ...

主力资金净流出居前的分别为新华医疗（1158.08万元）、理邦仪器（1077.62万元）、九强生物 （1072.63万元）、天臣医疗（1024.65万元）、振德医疗（1004.13万元）。 8月21日，医疗器械行业上涨0.07%，今日主力资金流出5.96亿元，成分股55只上涨，41只下跌。 来源：金融界 序号代码名称最新价涨跌幅主力净流入主力净占比1301363美好医疗23.418.09006.44万元7.62%2300760 迈瑞医疗245.713.877879.86万元1.93%3300677英科医疗37.431.085998.19万元8.66%4688050爱博医疗 77.311.154360.64万元14.35%5688656浩欧博125.628.424108.83万元10.2%6300171东富龙15.733.93758.67 万元8.14%7688617惠泰医疗283.99-0.143591.83万元7.35%8688301奕瑞科技111.921.612859.45万元 6.8%9300676华大基因51.760.392676.31万元6.06%10002223鱼跃医疗36.691.352369. ...

证券代码：300676 证券简称：华大基因 公告编号：2025-042 深圳华大基因股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司（以下简称公司或上市公司）近日收到公司控股股 东深圳华大基因科技有限公司（以下简称华大控股）的通知，获悉华大控股将其持 有的部分公司股份办理了质押，相应的质押登记手续已通过中国证券登记结算有限 责任公司深圳分公司办理完毕。现将具体事项公告如下： | | | | | | | | 已质押股份 | | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 持股数量 | 持股 | 本次质押 前的质押 | 本次质押后 | 占其 所持 | 占公 司总 | 情况 已质押股 | | 未质押股 | 情况 | | | | （股） | 比例 | 股份数量 | 的质押股份 | 股份 | 股本 | 份限售和 | 占已质 | 份限售和 | | 占未质 | ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 300725 | 药白科技 | 48.21 | -3.43% | | 19.65万 | 9.65亿 | | 300078 | 思创医惠 | 3.52 | -1.40% | | 88.83万 | 3.15 亿 | | 300676 | 华大基因 | 51.80 | -1.13% | | 7.04万 | 3.69 Z | | 300253 | 卫宁健康 | 10.58 | -1.12% | | 71.15万 | 7.58亿 | | 688222 | 成都先导 | 22.79 | -1.04% | | 23.32万 | 5.42 Z | | 300168 | 万达信息 | 8.15 | -0.97% | | 28.33万 | 2.32亿 | | 300244 | 迪安诊断 | 16.38 | -0.97% | | 17.19万 | 2.84亿 | | 301602 | 超研股份 | 28.19 | -0.84% | | 5.87万 | 1 ...

Core Viewpoint - The emergence of "technical managers" as a bridge between scientific research and market needs is transforming the employment landscape in the context of technological innovation and entrepreneurship [2][8]. Group 1: Industry Trends - Technology-driven and knowledge-intensive entrepreneurship has become a significant trend in recent years, with many researchers aspiring to transition from PI (Principal Investigator) to IP (Innovation Project) and eventually to IPO (Initial Public Offering) [2]. - The formal recognition of "technical managers" as a profession in the national occupational classification system in 2022 marks a shift towards professionalization and specialization in this role [2][8]. Group 2: Regional Developments - In July 2023, Shenzhen recognized its first batch of 154 "senior professional technical managers" from 133 different institutions, indicating a growing emphasis on this role in the region [3][15]. - The establishment of the first "Technical Manager Academy" at Shenzhen Technology University aims to cultivate a new generation of technical managers, with a focus on interdisciplinary education [14]. Group 3: Challenges in Scientific Entrepreneurship - Many scientists face challenges in entrepreneurship due to a lack of market insight, often focusing solely on technological advancements rather than market needs, leading to high failure rates in startups [5][6]. - The need for effective collaboration between scientists and technical managers is emphasized, as the latter can help translate scientific innovations into commercially viable products [8][11]. Group 4: Educational Initiatives - Several universities, including Tsinghua University and Shanghai Jiao Tong University, have begun offering specialized master's programs in technology transfer to address the shortage of qualified technical managers [14]. - The "Five Forces Model" proposed for training technical managers includes skills in technology, market insight, finance, law, and management, highlighting the multifaceted nature of the role [9][10]. Group 5: Future Outlook - The goal set by the Ministry of Science and Technology is to exceed 30,000 technical managers nationwide by 2025, reflecting the increasing importance of this role in facilitating technology transfer and commercialization [9]. - Shenzhen's dual approach of professional recognition and educational development is expected to provide a model for enhancing technology transfer capabilities across the country [15].

深圳华大基因股份有限公司 关于持股 5%以上股东减持股份计划的预披露公告 持股 5%以上的股东深圳生华投资企业（有限合伙）保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 证券代码：300676 证券简称：华大基因 公告编号：2025-041 深圳华大基因股份有限公司（以下简称公司或上市公司）持股 5%以上股东深 圳生华投资企业（有限合伙）（以下简称生华投资）持有公司股份 34,470,455 股， 占公司总股本 418,317,075 股的 8.2403%。生华投资计划自本减持计划公告之日起 15 个交易日后的 3 个月内（2025 年 9 月 4 日—2025 年 12 月 3 日），通过集中竞 价、大宗交易方式减持公司股份不超过 6,274,756 股（即不超过公司总股本比例的 1.5000%）。 公司近日收到持股 5%以上的股东生华投资出具的《股份减持计划的告知函》， 现将有关情况公告如下： 一、股东的基本情况 （一） 股东名称 深圳生华投资企业（有限合伙） （二） 股东持股情况 | 深圳 ...

Core Viewpoint - A case in the A-share market highlights the integration of health benefits into shareholder rewards, showcasing the effectiveness of the company's technology in a real-life scenario [1] Group 1: Company Initiatives - BGI Genomics (华大基因) launched a shareholder reward program in February 2025, allowing shareholders who have held shares for over a year to receive a free health screening kit [1] - The company emphasizes the importance of health as part of its shareholder return system, enabling shareholders to experience the benefits of its technology firsthand [1] Group 2: Case Study - A 35-year-old shareholder participated in the annual shareholder reward activity and received a health screening, which led to the early detection of a tumor through a colonoscopy [1] - The shareholder had purchased BGI Genomics stock in July 2022 and underwent surgery in early July 2023, with a good recovery reported [1]

Core Insights - The article highlights a significant case where a shareholder of BGI Genomics, Mr. Han, credits the company's health screening service with saving his life by detecting early-stage cancer through a free genetic test [2][8]. Group 1: Company Initiatives - BGI Genomics launched the "2025 Annual Shareholder Return Activity," allowing long-term shareholders to receive free health screenings, which reflects the company's commitment to shareholder welfare and health [3][8]. - The company emphasizes its mission of "genetic technology benefiting humanity," aiming to improve public health and quality of life through the application of life sciences [9]. Group 2: Health Screening Impact - Mr. Han's experience illustrates the effectiveness of BGI's fecal DNA methylation testing, which can detect early signs of colorectal cancer, highlighting the importance of early screening in preventing severe health issues [10][12]. - The article notes that colorectal cancer is the second most common cancer in China, with a rising incidence among younger populations, underscoring the need for increased awareness and screening [10][12]. Group 3: Industry Context - The article discusses the challenges in colorectal cancer screening, including the low screening rates due to the invasive nature of traditional methods, and advocates for non-invasive tests like BGI's as a viable alternative [12]. - It emphasizes the importance of proactive health management, encouraging individuals to take charge of their health rather than waiting for symptoms to appear [12].

Group 1 - The core viewpoint of the news highlights the successful early detection of colorectal cancer through the non-invasive Hua Chang Kang testing product by BGI Genomics, demonstrating its significant value in early diagnosis [1] - A shareholder, Mr. Han, participated in the company's annual shareholder reward activity and received the Hua Chang Kang intestinal health testing product, which led to the early detection of his colorectal cancer [1] - The testing revealed three positive gene methylation results, prompting further examination that confirmed the presence of a tumor, which was successfully surgically removed [1] Group 2 - According to the National Cancer Center's 2024 data, colorectal cancer is the second most common cancer in China, with a rising incidence in urban areas and a concerning trend of younger patients [2] - The "Guidelines for Colorectal Cancer Screening and Early Diagnosis and Treatment (2020)" recommend early screening for high-risk groups, including those with a family history of colorectal cancer, previous polyps, or chronic intestinal diseases [2] - BGI Genomics' Hua Chang Kang product utilizes fecal DNA methylation testing to analyze specific gene changes, providing a sensitive and specific method for detecting precancerous lesions or early cancer signals [2]

Core Viewpoint - As of August 5, 2025, BGI Genomics (300676) reported a closing price of 53.34 yuan, experiencing a decline of 0.78% with a turnover rate of 1.89% and a trading volume of 78,500 lots, amounting to 418 million yuan in transaction value [1] Financial Performance - For the first quarter of 2025, BGI Genomics reported total operating revenue of 672 million yuan, a year-on-year decrease of 18.18% - The net profit attributable to shareholders was 52.695 million yuan, a year-on-year decrease of 524.87% - The non-recurring net profit was 63.297 million yuan, a year-on-year decrease of 2,879.13% - The current ratio was 2.854, the quick ratio was 2.617, and the debt-to-asset ratio was 26.68% [1] Capital Flow - On the reporting day, the net outflow of main funds was 27.6854 million yuan, accounting for 6.63% of the transaction value - The net outflow of large orders was 21.3134 million yuan, accounting for 5.1% of the transaction value, while the net outflow of medium orders was 25.4012 million yuan, accounting for 6.08% - Small orders saw a net inflow of 2.2842 million yuan, accounting for 0.55% of the transaction value [1] Company Overview - BGI Genomics, established in 2010 and located in Shenzhen, primarily engages in professional technical services - The company has a registered capital of 4.15821575 billion yuan and a paid-in capital of 3.26119339 billion yuan - The legal representative of the company is Zhao Lijian [1][2] Investment and Intellectual Property - BGI Genomics has made investments in 71 companies and participated in 42 bidding projects - The company holds 665 trademark registrations and 374 patents, along with 13 administrative licenses [2]